← Leaderboards
Vicente Notario
Georgetown University
$4,836,458
Attributed
$4,836,458
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $318.5K · FY2005–12$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
Funding mix
By agency
NIH$4,836,458 · 3
By mechanism
R01$3,590,495 · 2
P01$1,245,963 · 1
Top collaborators
No co-investigators on record.
Most similar at Georgetown University
Same institution · by research overlap
- Kevin J Cullen$20,041,785
- Anna Tate Riegel$14,353,372
- Todd A Waldman$8,346,833
- Joyce Marie Slingerland$12,812,016
- Jeanne Mandelblatt$29,742,067
Others in their field
Top investigators on “Ionizing Radiation”
- Daniel R Marlow · University Of California-Los Angeles$64,882,770
- Jonine Lisa Bernstein · Mount Sinai School Of Medicine Of Nyu$28,343,347
- Robert D Cousins · University Of California-Los Angeles$21,088,050
- Wolf-Dietrich Heyer · University Of California Davis$17,546,787
- David J Morrissey · Michigan State University$16,285,714
- Bradley M Sherrill · Michigan State University$16,285,714
Research focus
Ionizing RadiationEnzyme ActivityStressCarcinogenesisGene ExpressionTissue /Cell CultureOncogenesYeastsGene Induction /RepressionNeoplasm /Cancer GeneticsApoptosisNucleic Acid SequenceNeoplastic CellProtooncogenePathway InteractionsProteinsCellsMutantLaboratoriesMalignant NeoplasmsMediatingCell LineGenesEquilibrium
Grant awards (19)
Targeting EWS/FLI1-driven pathways to improve therapeutic gains in Ewing's Sarcom$308,958
R01 · FY2012 · CA · contact PI
Targeting EWS/FLI1-driven pathways to improve therapeutic gains in Ewing's Sarcom$308,958
R01 · FY2011 · CA · contact PI
Targeting EWS/FLI1-driven pathways to improve therapeutic gains in Ewing's Sarcom$318,513
R01 · FY2010 · CA · contact PI
Targeting EWS/FLI1-driven pathways to improve therapeutic gains in Ewing's Sarcom$318,513
R01 · FY2009 · CA · contact PI
Targeting EWS/FLI1-driven pathways to improve therapeutic gains in Ewing's Sarcom$318,513
R01 · FY2008 · CA · contact PI
FUNCTION OF THE PCPH ONCOGENE IN MAMM;CARCINOGENESIS$46,560
R01 · FY2007 · CA · contact PI
FUNCTION OF THE PCPH ONCOGENE IN MAMM;CARCINOGENESIS$284,919
R01 · FY2006 · CA · contact PI
FUNCTION OF THE PCPH ONCOGENE IN MAMM;CARCINOGENESIS$291,776
R01 · FY2005 · CA
FUNCTION OF THE PCPH ONCOGENE IN MAMM;CARCINOGENESIS$291,776
R01 · FY2004 · CA
FUNCTION OF THE PCPH ONCOGENE IN MAMM;CARCINOGENESIS$291,776
R01 · FY2003 · CA
FUNCTION OF THE CPH ONCOGENE IN MAMMALIAN CARCINOGENESIS$21,922
R01 · FY2003 · CA
EWS/FLI-1: TARGET FOR RADIOSENSITIZATION &GROWTH INHIBITION OF EWING TUMORS$348,824
P01 · FY2002 · CA
FUNCTION OF THE CPH ONCOGENE IN MAMMALIAN CARCINOGENESIS$262,969
R01 · FY2002 · CA
MECHANISMS OF RDIATION RESPONSE AND ADP RIBOSE METABOLISM$348,824
P01 · FY2001 · CA
FUNCTION OF THE CPH ONCOGENE IN MAMMALIAN CARCINOGENESIS$243,019
R01 · FY2001 · CA
MECHANISMS OF RDIATION RESPONSE AND ADP RIBOSE METABOLISM$348,824
P01 · FY2000 · CA
FUNCTION OF THE CPH ONCOGENE IN MAMMALIAN CARCINOGENESIS$248,201
R01 · FY2000 · CA
MECHANISMS OF RDIATION RESPONSE AND ADP RIBOSE METABOLISM$199,491
P01 · FY2000 · CA
FUNCTION OF THE CPH ONCOGENE IN MAMMALIAN CARCINOGENESIS$34,122
R01 · FY2000 · CA